Veradermics, Incorporated (NYSE: MANE) is a Healthcare company (Biotechnology) with a market capitalization of $5.3B. The Maz Rating grades it against the other companies in its sector.
Veradermics, Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $125.64, Veradermics, Incorporated trades at 6.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -19.9%, return on invested capital of -14.0% and a free cash flow yield of -1.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 77.68. Over the past 52 weeks the share price ranged from $32.00 to $156.63, with a beta of 1.23.
Veradermics, Incorporated does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Veradermics, Incorporated (MANE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.01% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.6% / 30% · Interest income / Revenue 509600000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.01% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 509600000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.01% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 509600000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.03% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.5% / 33.33% · Receivables / Avg Assets (4Q) 0.13% / 33.33% · Interest income / Revenue 509600000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.08% / 33.33% · (Cash+ST Inv) / Total Assets 98.9% / 33.33% · (Cash+Recv) / Total Assets 98.9% / 33.33% · Interest income / Revenue 509600000.0% / 5% | Fail |
No. As of September 2026, Veradermics, Incorporated (MANE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Veradermics, Incorporated is over the AAOIFI limit on Interest income / Revenue.
About 509600000.0% of each dividend: Veradermics, Incorporated's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.